Skip to main content


  • Poster presentation
  • Open Access

The effects of cannabinergic agents in the central amygdala of rats in the elevated plus-maze test of anxiety

  • 1,
  • 2,
  • 1,
  • 3 and
  • 3
Annals of General Psychiatry20087 (Suppl 1) :S331

  • Published:


  • Public Health
  • Locomotor Activity
  • Brain Site
  • Potent Agonist
  • Main Receptor


Reports indicate that cannabinergic agents can change anxiety-related behaviours in both animals and humans. The amygdala is an important brain site in the modulation of fear or anxiety.

Materials and methods

In the present study, we investigated the effects of intracentral amygdala microinjection of cannabinergic agents on anxiety-related behaviours in rats, using the elevated plus-maze test of anxiety. Intracentral amygdala administration of ACPA a cannabinergic potent agonist (0.125, 1.25,5 ng/0.5 μl bilateral) increased %open arm time and % open arm entries, but not locomotor activity, showing an anxilytic response. Intracentral amygdala microinjection of AM251 a potent CB1 antagonist (2.5, 25, 100 ng/0.5 μl bilateral) did not change anxiety-related parameters in our experiments.


The results suggest that cannabinergic agonists may reduce anxiety via CB1 receptors in the rat central amygdala.


Couse that CB1 antagonist didn't show any effect on anxiety we think that CB1 isn't the main receptor in central amygdala.

Authors’ Affiliations

Depatment of pharmacology & toxicology, Ahvaz Jondi shapour University of Medical Sciences, Ahvaz, Khoozestan, Iran
Department of pharmacology, Tehran University of Medical Sciences, Tehran, Iran
Departement of Biology, Azad Islamic University, Tehran, Iran


© Sarahroodi et al.; licensee BioMed Central Ltd. 2008

This article is published under license to BioMed Central Ltd.